NEYPPC Pharmacy - ULM Aseptic Compounded Specials
In plain English
The notice doesn't say
Who holds it now
Last won by Clinigen Healthcare Limited and Mawdsley-Brooks & Co Ltd and Durbin PLC and 4 more in Mar 2026, for £27.4m.
- NEYPPC Pharmacy - Unlicensed Imported Medicines 2025Clinigen Healthcare Limited, Mawdsley-Brooks & Co Ltd, Durbin PLC and 4 more £27.4m
- Framework Agreement for the Supply of Unlicensed Imported Medicines Services and Products to Trusts within the North of England with the inclusion of mini competitions and/or direct awards.Target Healthcare Ltd, Eaststone Ltd, Alium Medical Ltd and 4 more £15.4m
What you're up against
- The same firms have won it the last 2 times Kestrel found: expect them to bid again, and to know the work well.
- 8 different firms won this buyer's 2 awards for this kind of work in 2026.
- It last went for £27.4m in 2026.
- The last award named 7 suppliers: it may be a framework, where many firms are chosen.
The notice as published
The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a Framework Agreement for the supply of Unlicensed Aseptic Compounded Specials. The requirement will cover the provision of unlicensed aseptic compounded specials, including sterile ready-to-administer injectable and infusion products that are batch manufactured or otherwise aseptically prepared in accordance with applicable UK regulatory standards and Good Manufacturing Practice (GMP) requirements. Suppliers will be required to hold all relevant licences, authorisations and regulatory approvals necessary to manufacture and supply unlicensed medicines within the UK, together with the appropriate quality assurance and batch release arrangements. The Framework Agreement will provide participating NHS organisations with access to safe, compliant and competitively sourced unlicensed aseptic compounded products, supporting continuity of supply, product quality assurance, patient safety and value for money across the NHS.